Onfekafusp Biosimilar – Anti-FN extra domain B mAb – Research Grade

Description of Onfekafusp Biosimilar - Anti-FN extra domain B mAb - Research Grade

Introduction

Onfekafusp Biosimilar is a novel therapeutic antibody that targets the extra domain B (ED-B) of fibronectin (FN). It is a research-grade biosimilar of the anti-FN mAb, which has shown promising results in pre-clinical and clinical studies for the treatment of various diseases. In this article, we will discuss the structure, activity, and potential applications of Onfekafusp Biosimilar in detail.

Structure of Onfekafusp Biosimilar

Onfekafusp Biosimilar is a monoclonal antibody (mAb) that is produced using recombinant DNA technology. It is a fully humanized IgG1 antibody, which means that it is derived from human cells and has a similar structure to natural antibodies found in the human body. The antibody consists of two heavy chains and two light chains, which are connected by disulfide bonds. The variable regions of the antibody are responsible for binding to the ED-B domain of FN, while the constant region mediates effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Activity of Onfekafusp Biosimilar

The main target of Onfekafusp Biosimilar is the ED-B domain of FN, which is a protein that is highly expressed in the extracellular matrix of tumor tissues and is involved in tumor growth, invasion, and metastasis. By binding to ED-B, Onfekafusp Biosimilar inhibits the interaction of FN with its receptors, leading to the disruption of tumor cell adhesion and migration. It also triggers ADCC and CDC, which further contribute to the destruction of tumor cells. In addition to its anti-tumor activity, Onfekafusp Biosimilar has also shown potential in targeting other diseases such as rheumatoid arthritis, atherosclerosis, and fibrotic disorders.

Potential Applications of Onfekafusp Biosimilar

Onfekafusp Biosimilar has shown promising results in pre-clinical and clinical studies for the treatment of various diseases. In a phase I clinical trial, Onfekafusp Biosimilar demonstrated a favorable safety profile and showed promising anti-tumor activity in patients with advanced solid tumors. It has also been evaluated in combination with other anti- cancer therapies and has shown synergistic effects. Furthermore, Onfekafusp Biosimilar has the potential to be used in combination with other therapeutic agents for the treatment of non-cancerous diseases such as rheumatoid arthritis and atherosclerosis.

Anti-Tumor Activity

Onfekafusp Biosimilar has shown promising results in targeting various types of cancers, including lung, breast, colon, and ovarian cancer. In pre-clinical studies, it has demonstrated significant anti-tumor activity by inhibiting tumor growth and metastasis. It has also shown potential in overcoming resistance to other anti- cancer therapies, making it a promising treatment option for patients with advanced or refractory cancers.

Combination Therapy Onfekafusp Biosimilar has been evaluated in combination with other anti-

cancer therapies, such as chemotherapy and immune checkpoint inhibitors, and has shown synergistic effects. This combination approach has the potential to enhance the anti-tumor activity of Onfekafusp Biosimilar and improve treatment outcomes for cancer patients.

Non-Cancerous Diseases

In addition to its anti-tumor activity, Onfekafusp Biosimilar has also shown potential in targeting non-cancerous diseases. In pre-clinical studies, it has demonstrated anti-inflammatory and anti-fibrotic effects, making it a potential treatment option for diseases such as rheumatoid arthritis, atherosclerosis, and fibrotic disorders.

Conclusion

Onfekafusp Biosimilar is a novel therapeutic antibody that targets the ED-B domain of